Financials in USD. Standardized financial statements.
A compact view of how Allarity Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $320,000 | $0 | $0 | $0 | $0 | $0 | $120,000 | $1.46M | $1.46M | $143,277 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | -91.8% | +0.1% | +918.3% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $120,000 | $106,000 | $0 | $0 | $5.08M | $2.22M | $0 |
| Gross Profit? | $320,000 | $0 | $0 | -$120,000 | -$106,000 | $0 | $120,000 | -$3.62M | -$761,495 | $143,277 |
| Gross Margin? | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +100.0% | -247.9% | -52.2% | +100.0% |
| Operating Expenses? | $12.93M | $27.24M | $17.13M | $34.46M | $26.56M | $8.32M | $17.73M | $1.36M | $3.08M | $4.63M |
| Operating Income? | -$12.61M | -$27.24M | -$17.13M | -$34.46M | -$26.56M | -$8.32M | -$17.61M | -$4.98M | -$3.84M | -$4.49M |
| EBITDA? | -$11.05M | -$24.23M | -$11.28M | -$17.30M | -$25.77M | -$6.01M | -$15.61M | -$4.90M | -$3.83M | -$4.21M |
| Income Before Tax | -$11.23M | -$24.90M | -$11.82M | -$17.58M | -$26.52M | -$6.42M | -$18.98M | -$3.46M | -$4.99M | -$4.45M |
| Income Tax Expense | $0 | -$381,000 | $83,000 | -$1.52M | $133,000 | $198,000 | -$4.58M | -$1.07M | -$95,086 | -$766,892 |
| Net Income? | -$11.23M | -$24.52M | -$11.90M | -$16.06M | -$26.65M | -$6.60M | -$14.31M | -$2.29M | -$4.90M | -$3.68M |
| EPS? | $-0.78 | $-15.79 | $-6031.31 | $-31799.09 | $-79074.18 | $-1698639.00 | $-189613.00 | $0.00 | $0.00 | $0.00 |
| Diluted EPS? | $-0.78 | $-15.79 | $-6031.31 | $-31799.09 | $-79074.18 | $-1698639.00 | $-189613.00 | $0.00 | $0.00 | $0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality